IMA Wealth Inc. Sells 2,228 Shares of Pfizer Inc. (NYSE:PFE)

IMA Wealth Inc. trimmed its position in shares of Pfizer Inc. (NYSE:PFEGet Rating) by 3.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 67,135 shares of the biopharmaceutical company’s stock after selling 2,228 shares during the quarter. Pfizer makes up about 0.9% of IMA Wealth Inc.’s investment portfolio, making the stock its 29th biggest position. IMA Wealth Inc.’s holdings in Pfizer were worth $3,964,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the business. Dillon & Associates Inc. bought a new stake in Pfizer during the fourth quarter worth about $221,000. Capricorn Fund Managers Ltd bought a new stake in Pfizer during the fourth quarter worth about $543,000. Mmbg Investment Advisors CO. bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $12,483,000. Aureus Asset Management LLC bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $221,000. Finally, HBK Investments L P bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $2,389,000. 66.50% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts have recently commented on the stock. Berenberg Bank set a $50.00 price target on shares of Pfizer in a research note on Thursday, May 19th. Citigroup increased their price target on shares of Pfizer from $46.00 to $57.00 and gave the company a “neutral” rating in a research note on Tuesday, April 5th. JPMorgan Chase & Co. set a $57.00 price target on shares of Pfizer in a research note on Tuesday, May 3rd. Wells Fargo & Company decreased their price target on shares of Pfizer from $60.00 to $55.00 in a research note on Wednesday, May 4th. Finally, SVB Leerink initiated coverage on shares of Pfizer in a report on Monday. They issued a “market perform” rating and a $55.00 price objective on the stock. Eleven investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $57.00.

In related news, SVP Jennifer B. Damico sold 4,000 shares of the firm’s stock in a transaction on Monday, May 16th. The shares were sold at an average price of $50.50, for a total value of $202,000.00. Following the completion of the transaction, the senior vice president now owns 15,064 shares of the company’s stock, valued at $760,732. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP William R. Carapezzi, Jr. sold 32,908 shares of the firm’s stock in a transaction on Thursday, May 12th. The shares were sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the completion of the transaction, the executive vice president now directly owns 38,146 shares of the company’s stock, valued at approximately $1,907,300. The disclosure for this sale can be found here. 0.05% of the stock is owned by corporate insiders.

PFE traded up $0.36 during mid-day trading on Thursday, hitting $54.07. The stock had a trading volume of 1,184,872 shares, compared to its average volume of 30,863,920. The stock’s fifty day simple moving average is $51.44 and its 200-day simple moving average is $52.26. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.39 and a quick ratio of 1.13. Pfizer Inc. has a 1-year low of $38.47 and a 1-year high of $61.71. The firm has a market capitalization of $303.38 billion, a price-to-earnings ratio of 12.39, a price-to-earnings-growth ratio of 0.61 and a beta of 0.76.

Pfizer (NYSE:PFEGet Rating) last issued its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.66 by ($0.04). Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The company had revenue of $25.66 billion for the quarter, compared to the consensus estimate of $24.73 billion. During the same period in the prior year, the company earned $0.93 EPS. The firm’s revenue was up 76.8% on a year-over-year basis. As a group, research analysts expect that Pfizer Inc. will post 6.63 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 10th. Stockholders of record on Friday, May 13th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 2.96%. The ex-dividend date of this dividend is Thursday, May 12th. Pfizer’s dividend payout ratio is 36.70%.

About Pfizer (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Articles

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.